VRTX - Vertex Pharmaceuticals Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
VRTX price evolution
VRTX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4580.1 | $9158 | $10369.1 | $11110.2 |
| Short term investments | $1215.4 | $1013.3 | $849.2 | $818 |
| Net receivables | $1656.1 | $1793.2 | $1563.4 | $1538.7 |
| Inventory | $914.6 | $813.1 | $738.8 | $688.7 |
| Total current assets | $8941.6 | $13288.7 | $14144.2 | $14695.8 |
| Long term investments | $4393.1 | $4381.4 | $2497.8 | $1700 |
| Property, plant & equipment | $1770.7 | $1485.7 | $1452.9 | $1434.5 |
| Goodwill & intangible assets | $1925.5 | $1922.9 | $1927.9 | $1691.6 |
| Total noncurrent assets | $11190.5 | $10628.7 | $8586 | $7030.4 |
| Total investments | $5608.5 | $5394.7 | $3347 | $2518 |
| Total assets | $20132.1 | $23917.4 | $22730.2 | $21726.2 |
| Current liabilities | ||||
| Accounts payable | $327.9 | $351.4 | $3020.2 | $375.9 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3547.2 | $3795.9 | $3547.4 | $3599.4 |
| Long term debt | $933.4 | $721.3 | $376.1 | $744.7 |
| Total noncurrent liabilities | $1810.2 | $1574.9 | $1602.4 | $1614 |
| Total debt | $933.4 | $721.3 | $724.7 | $744.7 |
| Total liabilities | $5357.4 | $5370.8 | $5149.8 | $5213.4 |
| Shareholders' equity | ||||
| Retained earnings | $7648.4 | $11242 | $10142.4 | $9173.6 |
| Other shareholder equity | $22.5 | $17.3 | $17580.4 | -$3 |
| Total shareholder equity | $14774.7 | $18546.6 | $17580.4 | $16512.8 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10369.1 | $10504 | $6795 | $5988.19 |
| Short term investments | $849.2 | $274.5 | $729.9 | $670.71 |
| Net receivables | $1563.4 | $1442.2 | $1136.8 | $885.35 |
| Inventory | $738.8 | $460.6 | $353.1 | $280.78 |
| Total current assets | $14144.2 | $12681.3 | $9560.6 | $8133.38 |
| Long term investments | $2497.8 | $20.8 | ||
| Property, plant & equipment | $1452.9 | $1108.4 | $1424.4 | $1284.1 |
| Goodwill & intangible assets | $1927.9 | $1691.6 | $1402.2 | $1402.16 |
| Total noncurrent assets | $8586 | $4916.1 | $3871.9 | $3618.43 |
| Total investments | $3347 | $274.5 | $729.9 | $670.71 |
| Total assets | $22730.2 | $18150.9 | $13432.5 | $11751.81 |
| Current liabilities | ||||
| Accounts payable | $3020.2 | $2430.6 | $195 | $155.14 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3547.4 | $2430.6 | $2142 | $1877.53 |
| Long term debt | $376.1 | $471.6 | $887.2 | $889.5 |
| Total noncurrent liabilities | $1602.4 | $1496.1 | $1190.5 | $1187.46 |
| Total debt | $724.7 | $810.3 | $887.2 | $889.5 |
| Total liabilities | $5149.8 | $4238.2 | $3332.5 | $3064.99 |
| Shareholders' equity | ||||
| Retained earnings | $10142.4 | $6522.8 | $3200.8 | $858.67 |
| Other shareholder equity | $17580.4 | $13912.7 | $15.9 | -$68.48 |
| Total shareholder equity | $17580.4 | $13912.7 | $10100 | $8686.82 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2645.6 | $2690.6 | $2517.7 | $2483.5 |
| Cost of revenue | $371.9 | $342.6 | $318.7 | |
| Gross Profit | $2273.7 | $2348 | $2149.7 | $2164.8 |
| Operating activities | ||||
| Research & development | $966.6 | $789.1 | $810 | |
| Selling, general & administrative | $372.2 | $342.7 | $263.8 | |
| Total operating expenses | $5787.9 | $1208.6 | $1161.2 | $1125.5 |
| Operating income | -$3514.2 | $1139.4 | $1039.3 | |
| Income from continuing operations | ||||
| EBIT | -$3381.3 | $1289.5 | $1190.1 | |
| Income tax expense | $202.4 | $179.5 | $178.8 | $143.9 |
| Interest expense | $9.9 | $10.4 | $168.9 | $10.9 |
| Net income | ||||
| Net income | -$3593.6 | $1099.6 | $968.8 | $1035.3 |
| Income (for common shares) | -$3593.6 | $1099.6 | $1035.3 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9869.2 | $8930.7 | $6205.68 | |
| Cost of revenue | $1080.3 | $736.3 | ||
| Gross Profit | $8607 | $7850.4 | $5469.38 | |
| Operating activities | ||||
| Research & development | $2540.3 | $1829.54 | ||
| Selling, general & administrative | $944.7 | $770.46 | ||
| Total operating expenses | $4775 | $3600.5 | $2599.99 | |
| Operating income | $4249.9 | $2869.39 | ||
| Income from continuing operations | ||||
| EBIT | $4287.2 | $3174.95 | ||
| Income tax expense | $760.2 | $910.4 | $405.15 | |
| Interest expense | $570.6 | $54.8 | $58.15 | |
| Net income | ||||
| Net income | $3619.6 | $3322 | $2711.65 | |
| Income (for common shares) | $3322 | $2711.65 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$3593.6 | $1099.6 | $968.8 | $1035.3 |
| Operating activities | ||||
| Depreciation | $54 | $53.5 | $59 | $42.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $154.2 | $191.9 | $208.6 | $130.9 |
| Total cash flows from operations | -$3753.6 | $1306.6 | $234.6 | $1268.4 |
| Investing activities | ||||
| Capital expenditures | -$69 | -$68.4 | -$58.1 | -$40.6 |
| Investments | -$372 | -$1888 | -$770.4 | -$77.1 |
| Total cash flows from investing | -$463.7 | -$2136.4 | -$886.5 | -$117.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$345.8 | -$347.8 | -$106.3 | -$154.8 |
| Net borrowings | -$13.7 | -$13.2 | -$10.2 | -$11.3 |
| Total cash flows from financing | -$358.6 | -$357.5 | -$119.8 | -$165 |
| Effect of exchange rate | -$2.5 | -$15.6 | $27.4 | -$22.5 |
| Change in cash and equivalents | -$4578.4 | -$1202.9 | -$744.3 | $963.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $3619.6 | $3322 | $2342.1 | $2711.65 |
| Operating activities | ||||
| Depreciation | $181.3 | $148.3 | $125.6 | $109.52 |
| Business acquisitions & disposals | -$295.9 | |||
| Stock-based compensation | $581.2 | $491.3 | $441.4 | $429.46 |
| Total cash flows from operations | $3537.3 | $4129.9 | $2643.5 | $3253.51 |
| Investing activities | ||||
| Capital expenditures | -$200.4 | -$204.7 | -$235 | -$259.8 |
| Investments | -$2883.3 | $179.5 | -$105.9 | $359.19 |
| Total cash flows from investing | -$3141.7 | -$321.1 | -$340.9 | $99.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$519.1 | $14.3 | -$1459.3 | -$474.46 |
| Net borrowings | -$43.1 | -$85.5 | -$24.4 | -$29.02 |
| Total cash flows from financing | -$562.2 | -$67.7 | -$1478 | -$505.28 |
| Effect of exchange rate | $26.9 | -$29.2 | -$13.4 | $20.55 |
| Change in cash and equivalents | -$139.7 | $3711.9 | $811.2 | $2868.16 |
News
Fundamentals
| Market cap | $120.75B |
|---|---|
| Enterprise value | $117.10B |
| Shares outstanding | 258.02M |
| Revenue | $10.34B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$489.90M |
| Revenue Q/Q | 6.11% |
| Revenue Y/Y | 8.76% |
| P/E ratio | -246.48 |
|---|---|
| EV/Sales | 11.33 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 11.68 |
| P/B ratio | 8.19 |
| Book/Share | 57.18 |
| Cash/Share | 17.75 |
| EPS | -$1.90 |
|---|---|
| ROA | -2.21% |
| ROE | -2.91% |
| Debt/Equity | 0.29 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.52 |
| Quick ratio | 2.26 |